Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2026
Five-year comparative outcomes of Nissen sleeve gastrectomy versus standard sleeve gastrectomy in patients with type 2 diabetes.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Savvala Natalia Antigoni, Jaussent Audrey, Prelot Anaïs, de Choudens Charlotte, Silvestri Marta, Joumaa Saaddedine, Lefebvre Patrick, Debourdeau Antoine, Picot Marie Christine, Nocca David, Galtier Florence, Bariatric surgery study group
Аннотация
BACKGROUND: Patients with type 2 diabetes (T2D) and obesity are prone to gastroesophageal reflux disease (GERD) due not only to obesity itself but also to gastroparesis, digestive neuropathy, and antidiabetic treatment. Nissen sleeve gastrectomy (NSG) achieves satisfactory long-term weight loss and significantly reduces GERD incidence. However, its results in this population remain to be compared with those of standard sleeve gastrectomy (SG) given the potential impact of the Nissen wrap on GERD outcomes.
OBJECTIVES: To compare the 5-year results of NSG on patients with T2D and obesity in terms of weight loss, T2D remission, and GERD incidence, with those of SG.
SETTING: Montpellier University Hospital, France.
METHODS: This is a comparative, nonrandomized, single-center cohort study analyzing prospectively collected data from patients who underwent SG or NSG between January 2017 and December 2019.
RESULTS: A total of 105 patients with T2D and obesity underwent either an SG (N = 61) or an NSG (N = 44), with 82 (SG: 44; NSG: 36) completing 5-year follow-up. The groups were comparable for sex, age, and T2D severity. At 5 years, total weight loss was 19.1% versus 19.6% (effect size: -.77, P = .86), mean hemoglobin A1C 6.5% versus 6.3% (effect size: -.43, P = .12), and clinical GERD incidence 57.9% versus 18.8% (effect size: .23 [.07; .73], P = .01) for the SG and NSG groups, respectively.
CONCLUSIONS: NSG could be a valuable alternative to SG for patients with T2D and obesity, providing comparable weight loss and diabetes remission at 5 years, with the added benefit of significantly reducing the incidence of GERD.
OBJECTIVES: To compare the 5-year results of NSG on patients with T2D and obesity in terms of weight loss, T2D remission, and GERD incidence, with those of SG.
SETTING: Montpellier University Hospital, France.
METHODS: This is a comparative, nonrandomized, single-center cohort study analyzing prospectively collected data from patients who underwent SG or NSG between January 2017 and December 2019.
RESULTS: A total of 105 patients with T2D and obesity underwent either an SG (N = 61) or an NSG (N = 44), with 82 (SG: 44; NSG: 36) completing 5-year follow-up. The groups were comparable for sex, age, and T2D severity. At 5 years, total weight loss was 19.1% versus 19.6% (effect size: -.77, P = .86), mean hemoglobin A1C 6.5% versus 6.3% (effect size: -.43, P = .12), and clinical GERD incidence 57.9% versus 18.8% (effect size: .23 [.07; .73], P = .01) for the SG and NSG groups, respectively.
CONCLUSIONS: NSG could be a valuable alternative to SG for patients with T2D and obesity, providing comparable weight loss and diabetes remission at 5 years, with the added benefit of significantly reducing the incidence of GERD.